m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis.
Everolimus
Meta-analysis
Pneumocystis pneumonia
Sirolimus
Solid organ transplant
mTOR inhibitors
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
19
04
2019
accepted:
20
07
2019
pubmed:
5
8
2019
medline:
10
3
2020
entrez:
5
8
2019
Statut:
ppublish
Résumé
Although there is controversy, some evidences proposed increased risk of post-transplant Pneumocystis carinii pneumonia (PCP) in patients receiving mammalian target of rapamycin (mTOR) inhibitors. This study aimed to examine the association between m-TOR inhibitors and the risk of developing PCP in solid organ transplant (SOT) recipients. A comprehensive search was performed to find the eligible studies that investigated the incidence of PCP in patients treated with mTOR inhibitors after SOT. Random effect model was applied for meta-analysis. Combination of 15 effect sizes showed a significant positive association between mTOR inhibitor administration and the risk of PCP (OR = 1.90, 95%CIs = 1.44, 2.75). There was no heterogeneity between studies (I In conclusion, administration of mTOR inhibitors is a potential risk factor for late-onset PCP after SOT. Targeted PCP prophylaxis based on recipients' risk factors rather universal prophylaxis may lessen the risk.
Identifiants
pubmed: 31377892
doi: 10.1007/s00228-019-02730-0
pii: 10.1007/s00228-019-02730-0
doi:
Substances chimiques
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1471-1480Références
Gordon SM, LaRosa SP, Arroliga AC, Avery RK, Longworth DL (1999) Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 28:240–246. https://doi.org/10.1086/515126
doi: 10.1086/515126
pubmed: 10064238
Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J (1992) Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long? Transplantation 53:586–589
doi: 10.1097/00007890-199203000-00019
Rodriguez M, Fishman JA (2004) Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17:770–782. https://doi.org/10.1128/CMR.17.4.770-782.2004
doi: 10.1128/CMR.17.4.770-782.2004
pubmed: 15489347
pmcid: 523555
Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059. https://doi.org/10.4065/82.9.1052
doi: 10.4065/82.9.1052
pubmed: 17803871
Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 1:1–66. https://doi.org/10.1002/14651858.CD005590.pub3
doi: 10.1002/14651858.CD005590.pub3
Goto N, Oka S (2011) P neumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 13:551–558. https://doi.org/10.1002/14651858.CD005590.pub3
doi: 10.1002/14651858.CD005590.pub3
pubmed: 22093172
Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, Roques O, del Bello A, Cointault O, Lavayssière L, Chauvin P, Menard S, Magnaval JF, Cassaing S, Rostaing L, Kamar N, Berry A (2015) Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 15:190–199. https://doi.org/10.1111/ajt.12947
doi: 10.1111/ajt.12947
pubmed: 25496195
Martin S, Fishman J (2013) Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13:272–279. https://doi.org/10.1111/ajt.12119
doi: 10.1111/ajt.12119
pubmed: 23465020
Radisic M, Lattes R, Chapman J et al (2005) Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case–control study. Transpl Infect Dis 5:84–93. https://doi.org/10.1111/ajt.12119
doi: 10.1111/ajt.12119
Faure E, Lionet A, Kipnis E, Noël C, Hazzan M (2017) Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation. Transplant Infect Dis 19:e12735. https://doi.org/10.1111/tid.12735
doi: 10.1111/tid.12735
Eitner F, Hauser IA, Rettkowski O, Rath T, Lopau K, Pliquett RU, Fiedler R, Guba M, Hilgers RD, Floege J, Fischereder M (2011) Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 26:2013–2017. https://doi.org/10.1093/ndt/gfq689
doi: 10.1093/ndt/gfq689
pubmed: 21071545
Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC (2009) Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 88:135–141. https://doi.org/10.1097/TP.0b013e3181aad256
doi: 10.1097/TP.0b013e3181aad256
pubmed: 19584693
De Castro N, Xu F, Porcher R, Pavie J, Molina J-M, Peraldi M-N (2010) Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case–control study. Clin Microbiol Infect 16:1375–1377. https://doi.org/10.1111/j.1469-0691.2009.03143.x
doi: 10.1111/j.1469-0691.2009.03143.x
pubmed: 20041898
Reid AB, Chen SC-A, Worth LJ (2011) Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 24:534–544. https://doi.org/10.1097/QCO.0b013e32834cac17
doi: 10.1097/QCO.0b013e32834cac17
pubmed: 21986616
Mulpuru S, Knoll G, Weir C, Desjardins M, Johnson D, Gorn I, Fairhead T, Bissonnette J, Bruce N, Toye B, Suh K, Roth V (2016) Pneumocystis pneumonia outbreak among renal transplant recipients at a north American transplant center: risk factors and implications for infection control. Am J Infect Control 44:425–431. https://doi.org/10.1016/j.ajic.2015.11.012
doi: 10.1016/j.ajic.2015.11.012
pubmed: 26804301
Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS (2000) Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial Experience1. Transplantation 70:1244–1247
doi: 10.1097/00007890-200010270-00021
Peddi VR, Wiseman A, Chavin K, Slakey D (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transpl Rev 27:97–107. https://doi.org/10.1016/j.trre.2013.06.001
doi: 10.1016/j.trre.2013.06.001
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Me 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
doi: 10.1371/journal.pmed.1000097
Schmidt CO, Kohlmann T (2008) When to use the odds ratio or the relative risk? Int J Public Health 53:165–167. https://doi.org/10.1007/s00038-008-7068-3
doi: 10.1007/s00038-008-7068-3
pubmed: 19127890
Szumilas M (2010) Explaining odds ratios. J Can Acad Child Adolesc Psychiatry 19:227
doi: 10.1007/s00787-010-0087-7
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-z
doi: 10.1007/s10654-010-9491-z
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12. https://doi.org/10.1016/0197-2456(95)00134-4
doi: 10.1016/0197-2456(95)00134-4
pubmed: 8721797
Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315:629–634. https://doi.org/10.1136/bmj.315.7109.629
doi: 10.1136/bmj.315.7109.629
pubmed: 9310563
pmcid: 2127453
Renoult E, Buteau C, Lamarre V, Turgeon N, Tapiero B (2005) Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents? Pediatr Transplant 9:470–479. https://doi.org/10.1111/j.1399-3046.2005.00325.x
doi: 10.1111/j.1399-3046.2005.00325.x
pubmed: 16048599
Kuypers DR (2005) Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 28:153–181. https://doi.org/10.2165/00002018-200528020-00006
doi: 10.2165/00002018-200528020-00006
pubmed: 15691225
Augustine JJ, Bodziak KA, Hricik DE (2007) Use of sirolimus in solid organ transplantation. Drugs 67:369–391. https://doi.org/10.2165/00003495-200767030-00004
doi: 10.2165/00003495-200767030-00004
pubmed: 17335296
Moes DJA, Guchelaar H-J, de Fijter JW (2015) Sirolimus and everolimus in kidney transplantation. Drug Discov Today 20:1243–1249. https://doi.org/10.1016/j.drudis.2015.05.006
doi: 10.1016/j.drudis.2015.05.006
pubmed: 26050578
de Boer MG, Walzer P, Mori S (2018) Healthcare related transmission of Pneumocystis pneumonia: from key insights towards comprehensive prevention. Transpl Infect Dis 20:e12942. https://doi.org/10.1111/tid.12942
doi: 10.1111/tid.12942
pubmed: 29873156
Hosseini-Moghaddam S, Shokoohi M, Singh G et al (2019) A multicenter case-control study of the effect of acute rejection and Cytomegalovirus infection on Pneumocystis pneumonia in solid organ transplant recipients. Clin Infect Dis 68:1320–1326. https://doi.org/10.1093/cid/ciy682
doi: 10.1093/cid/ciy682
pubmed: 30107568
Werbel W, Ison M, Angarone M, Yang A, Stosor V (2018) Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis 20:e12876. https://doi.org/10.1111/tid.12876
doi: 10.1111/tid.12876
pubmed: 29512868
Hu YN, Lee NY, Roan JN, Hsu CH, Luo CY (2017) High dose calcineurin inhibitor free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia. Transpl Infect Dis 19:e12709. https://doi.org/10.1111/tid.12709
doi: 10.1111/tid.12709
Rostved AA, Sassi M, Kurtzhals JA et al (2013) Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation 15:834–842. https://doi.org/10.1097/TP.0b013e3182a1618c
doi: 10.1097/TP.0b013e3182a1618c
Castro Nd XF, Porcher R, Pavie J, Molina J, Peraldi M (2010) Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect 16:1375–1377. https://doi.org/10.1111/j.1469-0691.2009.03143.x
doi: 10.1111/j.1469-0691.2009.03143.x
Kahan BD, Group RUS (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 356:194–202. https://doi.org/10.1016/S0140-6736(00)02480-6
doi: 10.1016/S0140-6736(00)02480-6
Groth CG, Bäckman L, Morales J-M et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67:1036–1042
doi: 10.1097/00007890-199904150-00017
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837–847. https://doi.org/10.1016/S0140-6736(10)62318-5
doi: 10.1016/S0140-6736(10)62318-5
pubmed: 21334736
Neofytos D, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller NJ, Boggian K, Cusini A, Manuel O, van Delden C, Swiss Transplant Cohort Study (2018) Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss transplant cohort. Transpl Infect Dis 20:e12984. https://doi.org/10.1111/tid.12984
doi: 10.1111/tid.12984
pubmed: 30155950
Silva HT, Felipe CR, Pestana JO (2015) Reviewing 15 years of experience with sirolimus. Transplant Res 4:6–11. https://doi.org/10.1186/s13737-015-0028-6
doi: 10.1186/s13737-015-0028-6
Tedesco-Silva H, del Carmen RM, Cruz Santiago J, Mazzali M, Pacheco-Silva A, Torres R (2019) Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation. Clin Transpl 33:e13464. https://doi.org/10.1111/ctr.13464
doi: 10.1111/ctr.13464
Baur B, Oroszlan M, Hess O, Carrel T, Mohacsi P (2011) Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. Transplant Proc 43:1853–1861. https://doi.org/10.1016/j.transproceed.2011.01.174
doi: 10.1016/j.transproceed.2011.01.174
pubmed: 21693289
Moro J, Almenar L, Martínez-Dolz L, Sánchez-Lázaro I, Agüero J, Salvador A (2008) Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 40:3034–3036. https://doi.org/10.1016/j.transproceed.2008.09.049
doi: 10.1016/j.transproceed.2008.09.049
pubmed: 19010183
Klawitter J, Nashan B, Christians U (2015) Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14:1055–1070. https://doi.org/10.1517/14740338.2015.1040388
doi: 10.1517/14740338.2015.1040388
pubmed: 25912929
pmcid: 6053318
Struijk GH, Gijsen AF, Yong SL, Zwinderman AH, Geerlings SE, Lettinga KD, van Donselaar-van der Pant KAMI, ten Berge IJM, Bemelman FJ (2011) Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant 26:3391–3398. https://doi.org/10.1093/ndt/gfr048
doi: 10.1093/ndt/gfr048
pubmed: 21385859
McKinnell JA, Cannella AP, Kunz DF et al (2012) Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis 14:510–518. https://doi.org/10.1111/j.1399-3062.2012.00739.x
doi: 10.1111/j.1399-3062.2012.00739.x
pubmed: 22548840
pmcid: 3889465
de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT (2011) Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 13:559–569. https://doi.org/10.1111/j.1399-3062.2011.00645.x
doi: 10.1111/j.1399-3062.2011.00645.x
pubmed: 21689251
Oz HS, Hughes WT (1997) Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 175:901–904. https://doi.org/10.1086/513988
doi: 10.1086/513988
pubmed: 9086147
Wang E, Partovi N, Levy R, Shapiro R, Yoshida E, Greanya E (2012) Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis 14:519–525. https://doi.org/10.1111/j.1399-3062.2012.00740.x
doi: 10.1111/j.1399-3062.2012.00740.x
pubmed: 22571389
Chapman JR, Marriott DJ, Chen SC-A, MacDonald PS (2013) Post-transplant Pneumocystis jirovecii pneumonia—a re-emerged public health problem? Kidney Int 84:240–243. https://doi.org/10.1038/ki.2013.212
doi: 10.1038/ki.2013.212
pubmed: 23739237